Diligence memo · auto-generated · as of July 2, 2026
Strata Oncology, Inc.
Strata Oncology, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Strata Oncology, Inc. operates in Pharma, based in ANN ARBOR.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Strata Oncology, Inc. has raised $29M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $12M on 2018-04-30.
Most recent recorded round closed around 2024-11-08.
Valuation (modeled)modeled
Provath models Strata Oncology, Inc. at approximately $27M (range $7.0M–$54M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.39× the median modeled value of Series A Pharma companies in 2022–2024 (24 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 35 months.
Last raise 20 mo ago; this sector typically re-raises about every 16 months.
Slightly overdue versus sector cadence.
The last round stepped up 1.2× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 81% of Pharma peers (310 compared).
Modeled value ranks above 48% of those peers.
Closest niche peers: Carmine Therapeutics, Inc., Triomics, Inc., Spiral Therapeutics Inc, Convelo Therapeutics, Inc., ADvantage Therapeutics, Inc..
Peoplefiled
11 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.